NY-ESO-1 Antibodies

Santa Cruz Biotechnology provides a broad selection of NY-ESO-1 monoclonal antibodies for research in understanding this important cancer/testis antigen. NY-ESO-1 monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). NY-ESO-1 plays a critical role in tumor immunology, as it is expressed in a variety of tumors but not in normal tissues, making it a promising target for cancer immunotherapy. The unique expression pattern of NY-ESO-1 has established it as a focal point in the development of cancer vaccines and adoptive T cell therapies. Understanding the function and regulation of NY-ESO-1 is essential for advancing therapeutic strategies against cancers that express this antigen. NY-ESO-1 monoclonal antibodies enable precise detection and characterization of expression patterns across different tumor types. Researchers studying NY-ESO-1 can leverage specific binding capabilities to advance cancer biomarker identification and therapeutic development. Santa Cruz Biotechnology's NY-ESO-1 monoclonal antibodies support the scientific community in developing innovative approaches to cancer diagnosis and treatment.